Nectar Lifesci. Share Price ₹11

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Nectar Lifesci.

Quarter-by-quarter operating performance

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales +	344	389	394	398	452	441	359	6	0	431	5	1	0
Expenses +	343	371	359	371	410	393	319	6	0	585	6	0	2
Operating Profit	1	18	36	27	42	48	40	-1	-0	-154	-1	1	-2
OPM %	0%	5%	9%	7%	9%	11%	11%	-10%	-500%	-36%	-16%	77%
Other Income +	13	18	0	11	0	1	1	7	8	0	-62	-176	35
Interest	17	20	18	21	25	24	20	0	0	18	0	0	30
Depreciation	15	15	15	15	15	15	15	0	0	16	1	0	0
Profit before tax	-18	2	3	2	2	11	5	5	8	-188	-64	-176	3
Tax %	-47%	-145%	41%	38%	36%	95%	40%	-2%	2%	-31%	-1%	0%	-339%
Net Profit +	-9	4	2	1	2	1	3	6	8	-130	-63	-176	14
EPS in Rs	-0.41	0.16	0.08	0.05	0.07	0.03	0.13	0.25	0.35	-5.80	-2.82	-7.85	0.64

Financials of Nectar Lifesci.

Annual income statement trend

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	1,634	1,638	1,674	1,635	1,874	2,779	2,363	1,541	1,665	1,520	1,682	1,664	437
Expenses +	1,345	1,371	1,436	1,411	1,638	2,514	2,143	1,432	1,507	1,467	1,530	1,694	593
Operating Profit	289	267	239	224	236	264	220	109	159	53	152	-30	-157
OPM %	18%	16%	14%	14%	13%	10%	9%	7%	10%	3%	9%	-2%	-36%
Other Income +	12	20	6	23	6	6	4	-22	11	43	15	5	-203
Interest	138	126	123	117	115	148	126	112	79	79	87	75	48
Depreciation	84	77	57	62	64	63	61	60	57	59	61	62	16
Profit before tax	78	85	64	67	63	59	37	-85	34	-42	18	-162	-424
Tax %	21%	22%	15%	18%	17%	19%	15%	-14%	26%	-43%	73%	-30%
Net Profit +	62	66	54	55	52	48	32	-73	25	-24	5	-114	-355
EPS in Rs	2.77	2.95	2.42	2.47	2.33	2.12	1.42	-3.27	1.12	-1.08	0.22	-5.07	-15.83
Dividend Payout %	4%	3%	4%	2%	2%	2%	4%	0%	0%	0%	0%	0%

Financials of Nectar Lifesci.

Capital structure and asset base

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	22	22
Reserves	905	936	932	984	1,036	1,083	1,114	1,040	1,065	1,042	1,047	934	694
Borrowings +	858	925	962	878	955	903	779	903	860	754	636	582	459
Other Liabilities +	609	628	640	696	710	696	718	423	443	371	486	509	639
Total Liabilities	2,394	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	1,815
Fixed Assets +	948	934	906	881	852	825	785	772	723	662	643	633	28
CWIP	122	91	99	102	100	100	115	99	85	78	66	57	0
Investments	0	1	1	1	1	1	0	1	1	1	1	1	1
Other Assets +	1,324	1,485	1,551	1,597	1,771	1,780	1,733	1,517	1,582	1,449	1,482	1,357	1,786
Total Assets	2,394	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	1,815

Financials of Nectar Lifesci.

Operating, investing and financing cash movement

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	255	144	169	199	65	239	285	21	95	134	225	169
Cash from Investing Activity +	-90	-60	-77	-18	-29	-26	-33	-29	17	52	-17	-42
Cash from Financing Activity +	-161	-61	-89	-204	-40	-201	-252	11	-119	-186	-205	-128
Net Cash Flow	4	23	3	-23	-4	12	-0	4	-8	-0	2	-1
Free Cash Flow	153	64	87	174	32	204	249	-10	110	183	195	126
CFO/OP	95%	56%	74%	92%	33%	96%	134%	23%	60%	252%	148%	-574%

Financials of Nectar Lifesci.

Working capital efficiency and return ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	84	99	107	112	119	73	61	89	98	67	82	76
Inventory Days	240	253	260	270	226	151	192	185	197	212	215	184
Days Payable	139	146	154	167	142	80	104	108	112	100	127	117
Cash Conversion Cycle	185	207	213	215	203	145	150	166	182	179	170	143
Working Capital Days	23	40	41	45	67	46	53	6	73	77	63	43
ROCE %	12%	11%	10%	10%	9%	10%	8%	3%	5%	-0%	6%	-5%

Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Nectar Lifesci. Share Price & Earnings Call Analysis